Compare ADMA Biologics Inc (ADMA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Thomson Reuters Corp — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Thomson Reuters Corp trades at $104.52 (market cap $45.08B). The key difference: Thomson Reuters Corp is far larger — about 20.7× ADMA Biologics Inc's market cap, and Thomson Reuters Corp pays a 2.51% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TRI | |
|---|---|---|
Market Cap | $2.18B | $45.08B |
Sector | Health | Industrials |
52-Week High | $20.38 | $178.77 |
52-Week Low | $7.60 | $76.55 |
Enterprise Value | $2.25B | $47.69B |
Dividend Yield | — | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Thomson Reuters (TRI) trades at $101.83, up 1.68% today, near the consensus price target of $102.33. The stock shows strong technical momentum with bullish moving averages and support at $99. Fundamentally, TRI delivered Q2 2026 earnings beat ($0.99 vs. $0.96 expected) with 8% organic revenue growth, while maintaining robust profitability margins (21.22% net income margin). Recent news highlights AI-driven product momentum and raised full-year revenue guidance.
Outlook remains positive with analyst consensus favoring Buy (51.85%) and 29.8% upside potential to high target of $124. Key risks include execution on AI transition and competitive pressures in legal/tax software markets. The company's recurring revenue model (82% of total) and dividend payments provide stability amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
